Enhancing Polyp Detection: A Randomized Controlled Trial Comparing Combined Computer-Aid Detection and Polyp-Detecting Colonoscope Attachment to Computer-Aid Detection Alone in Patients Undergoing Colonoscopy.

Despite the widespread use of colonoscopy, the ongoing challenge of potentially missing polyps remains. Previous studies have independently shown that both Endocuff, a colonoscope attachment device for polyp detection, and Computer-Aided Detection (CADe) systems have individually demonstrated enhanced lesion detection and safety. This study seeks to evaluate the efficacy of combining the Endocuff CADe versus using CADe alone in colonoscopy procedures for colorectal cancer screening and surveillance. This research project aims to ascertain whether the synergistic application of these technologies yields superior outcomes.

Start Date23 Oct 2023

Sponsor / Collaborator

Marshall University

NCT05955040

/ TerminatedPhase 2IIT

Treatment of Elevated Blood Pressures in Early Pregnancy

This is a randomized controlled trial comparing the outcomes of treatment and non-treatment of elevated blood pressures in early pregnancy.

Start Date11 Jul 2023

Sponsor / Collaborator

Marshall University

100 Clinical Results associated with Marshall University

0 Patents (Medical) associated with Marshall University

1,735

Literatures (Medical) associated with Marshall University

01 Feb 2026·Life Science Alliance

Polyphyletic screen defines distinct classes of plant-derived natural products that oppose tauopathy

Article

Author: Shepard, Chatrawee D ; Chang, Xinmin ; Curran, Sean P ; Seidler, Paul M

Alzheimer’s disease (AD) is a debilitating neurodegenerative disease hallmarked by the presence of amyloid-β (Aβ) plaques and tau fibrils but with limited treatment options. Here, we describe two plant-derived natural products with distinct mechanisms of action on tau fibril disaggregation and prionogenic seeding. We first characterized the effects of oolonghomobisflavan A (OFA) and oolonghomobisflavan B (OFB) treatments, which alter the transcriptional landscape toward enhanced proteostasis and reverse the shortened lifespan in a Caenorhabditis elegans model expressing pathogenic human tau (“hTau-expressing”), but increase healthspan. Mechanistically, OFA treatment reduced the burden of tau protein aggregation and promoted tau disaggregation in hTau-expressing C. elegans and also inhibited seeding in assays using ex vivo brain-derived paired helical filament tau protein fibrils from Alzheimer’s disease brain donors. We leveraged this finding to develop a facile screening approach for compounds, like OFA, that could mitigate tau aggregation, which revealed plumbagin (PB) as a potent inhibitor of tau monomer aggregation which is mechanistically distinct from the tau fibril disaggregase activity associated with OFA. Collectively, this study reveals a new strategy for identifying therapeutic compounds that target tauopathy and provides mechanistic insight supporting the neuroprotective effects of plant-derived natural products.

01 Feb 2026·Journal of Orthopaedics

Opioid use following partial meniscectomy with needle arthroscopy compared to standard knee arthroscopy: Results from a randomized multicenter trial

Article

Author: Nottingham, James ; Lavender, Chad D ; Hahn, Ethan ; Hwang, Tyler H ; Hewett, Timothy E ; Schaver, Andrew L ; LeMaster, Eliana S ; Argintar, Evan H

Purpose:

To evaluate opioid use following partial meniscectomy performed with needle arthroscopy compared to standard arthroscopy.

Methods:

A prospective, multicenter randomized trial was performed between January and August 2023. Patients undergoing isolated partial meniscectomy were randomized to receive either needle (NA, n = 41) or standard arthroscopic (SA, n = 40) treatment. Those receiving meniscus repair or concurrent ligament, or cartilage procedures were excluded. The primary outcome was opioid consumption within 24 h post-operatively. Secondary outcomes were patient reported outcomes (PROs), including Knee Injury and Osteoarthritis Outcome (KOOS) pain and International Knee Documentation Committee (IKDC) scores measured at 2, 6, and 12-weeks postoperatively. Univariate analysis was used to compare results.

Results:

Eighty-nine patients were enrolled. One patient withdrew on the day of surgery. Eight patients (NA, n = 2; SA, N = 6) were excluded due to insufficient records regarding opioid consumption. There were 41 patients in the NA group and 40 patients in the SA group (NA 26 males, 63 % vs. SA 19 males, 48 %, p = 0.15). Mean age ± SD (NA 48.5 ± 10.7 vs SA 48.2 ± 9.9 years, p = 0.87) and body mass index (NA 30.8 ± 4.9 vs. SA 32.6 ± 6.6 m/kg², p = 0.64) were not significantly different. Pre-operative Outerbridge scores were similar (NA 2.8 ± 1.1 vs. SA 2.5 ± 1.2, p = 0.38). The NA group consumed significantly fewer opioid pills within 24 h (NA 1.3 ± 1.7 vs. SA 2.7 ± 2.1, p < 0.01). In addition, patients reported significant differences in KOOS pain and IKDC scores at 2 weeks [KOOS pain: NA 62.9 ± 21.2 vs. 50.2 ± 20.1, p = 0.007 and IKDC: NA 56.7 ± 18.7 vs. SA 41 ± 17.2, p < 0.001] and 6 weeks post-operatively [KOOS pain: NA 72.6 ± 20.5 vs. 63.5 ± 18.3, p = 0.050 and IKDC: NA 67.5 ± 23.9 vs. 54.8 ± 18.1, p = 0.015]. At 12 weeks, differences in PROs were not maintained.

Conclusion:

In the immediate post-operative period, opioid use was significantly reduced after partial meniscectomy performed with needle arthroscopy compared with standard arthroscopy.

Level of evidence:

Level I.

01 Feb 2026·COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

A subject-based association network defines new pediatric sleep apnea phenotypes with different odds of recovery after treatment

Article

Author: Hornero, Roberto ; Gozal, David ; Álvarez, Daniel ; Campo, Félix Del ; Gomez-Pilar, Javier ; Pereira-Rodrigues, Pedro ; Ferreira-Santos, Daniela ; Gutiérrez-Tobal, Gonzalo C

BACKGROUND AND OBJECTIVES:

Timely treatment of pediatric obstructive sleep apnea (OSA) can prevent or reverse neurocognitive and cardiovascular morbidities. However, whether distinct phenotypes exist and account for divergent treatment effectiveness remains unknown. In this study, our goal is threefold: i) to define new data-driven pediatric OSA phenotypes, ii) to evaluate possible treatment effectiveness differences among them, and iii) to assess phenotypic information in predicting OSA resolution.

METHODS:

We involved 22 sociodemographic, anthropometric, and clinical data from 464 children (5-10 years old) from the Childhood Adenotonsillectomy Trial (CHAT) database. Baseline information was used to automatically define pediatric OSA phenotypes using a new unsupervised subject-based association network. Follow-up data (7 months later) were used to evaluate the effects of the therapeutic intervention in terms of changes in the obstructive apnea-hypopnea index (OAHI) and the resolution of OSA (OAHI < 1 event per hour). An explainable artificial intelligence (XAI) approach was also developed to assess phenotypic information as OSA resolution predictor at baseline.

RESULTS:

Our approach identified three OSA phenotypes (PH_OSA1-PH_OSA3), with PH_OSA2 showing significantly lower odds of OSA recovery than PH_OSA1 and PH_OSA3 when treatment information was not considered (odds ratios, OR: 1.64 and 1.66, 95 % confidence intervals, CI: 1.03-2.62 and 1.01-2.69, respectively). The odds of OSA recovery were also significantly lower in PH_OSA2 than in PH_OSA3 when adenotonsillectomy was adopted as treatment (OR: 2.60, 95 % CI: 1.26-5.39). Our XAI approach identified 79.4 % (CI: 69.9-88.0 %) of children reaching OSA resolution after adenotonsillectomy, with a positive predictive value of 77.8 % (CI: 70.3 %-86.0 %).

CONCLUSIONS:

Our new subject-based association network successfully identified three clinically useful pediatric OSA phenotypes with different odds of therapeutic intervention effectiveness. Specifically, we found that children of any sex, >6 years old, overweight or obese, and with enlarged neck and waist circumference (PH_OSA2) have less odds of recovering from OSA. Similarly, younger female children with no enlarged neck (PH_OSA3) have higher odds of benefiting from adenotonsillectomy.

News (Medical) associated with Marshall University

05 Dec 2025

·www.drugs.com

Fewer Opioids Needed After "Needle" Knee Surgery

FRIDAY, Dec. 5, 2025 — Knee surgery patients use fewer opioids and recover more quickly following an innovative “needle” surgical technique, a new study says. Patients who underwent knee surgery using minimally invasive “needle arthroscopy” needed half the opioids to manage pain the day after their procedure, researchers reported in the February 2026 issue of the Journal of Orthopaedics . They also reported better early knee function compared to patients who underwent a standard arthroscopic procedure, results show. “This study reinforces that smaller, less invasive approaches can make a meaningful difference in how patients experience recovery,” lead researcher Dr. Chad Lavender , an assistant professor of orthopedic surgery at the Marshall University Joan C. Edwards School of Medicine in Huntington, West Virginia, said in a news release. For the study, researchers treated 41 patients with needle arthroscopy and another 40 with normal arthroscopic surgery. The patients all required surgery to clean up torn cartilage in their knees. Needle arthroscopy uses a small, needle-like scope to perform knee surgery, researchers said in background notes. The tiny tube, equipped with a light and camera, is inserted into a small incision at the knee. A needle arthroscope is around 1.9 millimeters in diameter, compared to the 4-millimeter scope used in traditional arthroscopy, Yale Medicine says. Patients can remain wide awake through needle arthroscopic surgery, using only a local anesthetic to numb the joint, Yale noted. Results showed that patients treated with needle arthroscopy needed about 1.3 opioid pills to manage their pain during the day after surgery, compared with 2.7 pills for those treated with traditional arthroscopy. Both groups recovered similarly after six weeks, but those treated with needle arthroscopy benefited from less discomfort and a quicker return to activity, researchers said. “By reducing post-operative pain and the need for opioid medications, we can help patients return to their normal lives faster while supporting broader efforts to combat opioid dependency,” Lavender said. Sources Marshall University Joan C. Edwards School of Medicine, news release, Nov. 19, 2025 Journal of Orthopaedics, Nov. 10, 2025

Clinical Result

04 Dec 2025

·www.drugs.com

Needle Arthroscopy for Partial Meniscectomy Cuts Postoperative Opioid Use

THURSDAY, Dec. 4, 2025 -- In the immediate postoperative period, opioid use was significantly reduced after partial meniscectomy performed with needle arthroscopy versus standard knee arthroscopy, according to a study published in the February 2026 issue of the Journal of Orthopaedics . Chad D. Lavender, M.D., from Marshall University in Huntington, West Virginia, and colleagues compared opioid use following partial meniscectomy performed with needle arthroscopy (41 patients) versus standard arthroscopy (40 patients). The researchers found that the needle arthroscopy group consumed significantly fewer opioid pills within 24 hours (1.3 versus 2.7 undergoing standard arthroscopy). Additionally, patients undergoing needle arthroscopy reported significant differences in Knee Injury and Osteoarthritis Outcome (KOOS) pain scores (62.9 versus 50.2) and International Knee Documentation Committee (IKDC) scores at two weeks (56.7 versus 41). A similar trend was seen at six weeks postoperatively (KOOS pain: 72.6 versus 63.5; IKDC: 67.5 versus 54.8). By 12 weeks, there were no differences in patient-reported outcomes. "This study reinforces that smaller, less invasive approaches can make a meaningful difference in how patients experience recovery," Lavender said in a statement. "By reducing postoperative pain and the need for opioid medications, we can help patients return to their normal lives faster while supporting broader efforts to combat opioid dependency." Two authors disclosed ties to Arthrex, Inc., which funded the study. Abstract/Full Text (subscription or payment may be required)

Clinical Result

21 Oct 2024

·www.prnewswire.com

The Inner Circle acknowledges, Jesamyn Fuscardo Marshall, DO as a Pinnacle Lifetime Member

COLLIERS, W.Va., Oct. 21, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jesamyn Fuscardo Marshall, DO is acknowledged as a Pinnacle Lifetime Member for her contributions in Leading Emergency Medicine with Dedication and Vision. Dr. Jesamyn Fuscardo Marshall, a dedicated emergency medicine physician, has been making significant contributions to healthcare in her local community. With a passion for patient care and a commitment to excellence, Dr. Fuscardo Marshall's role extends beyond clinical practice to leadership and innovation in emergency medicine. Continue Reading Jesamyn Fuscardo Marshall After earning her Bachelor of Science in Biomedical Science from Marshall University and her Doctor of Osteopathic Medicine from the West Virginia School of Osteopathic Medicine, Dr. Fuscardo Marshall completed her residency in Emergency Medicine at Ohio Valley Medical Center in Wheeling, West Virginia. Board-certified in emergency medicine, she brings a wealth of expertise to her practice. In her current role as Assistant Director of the emergency department, Dr. Fuscardo Marshall oversees various administrative functions, including managing staff schedules and shifts, spearheading quality improvement initiatives, and leading an end-of-life care committee. Her dedication to ensuring the highest standards of patient care is evident in her leadership and attention to detail. Beyond her clinical and administrative duties, Dr. Fuscardo Marshall is a co-founder of MOMance, a group dedicated to supporting women and new mothers in their physical and mental health journey. Through MOMance, she provides valuable resources and support to women in her community, demonstrating her commitment to holistic healthcare. Dr. Fuscardo Marshall's career accomplishments speak volumes about her dedication and expertise. She was recognized as Intern of the Year by Ohio Valley Medical Center in 2012, a testament to her exceptional skills and compassionate approach to patient care. Guided by her father, Dr. Mitchell Fuscardo, DO, who inspired her to pursue emergency medicine, and supported by her mother, Julie Yingst, Dr. Fuscardo Marshall is driven by a vision of creating positive change in healthcare. She is married to Mr. Bruce Marshall, Jr., and they have three children. Looking ahead, Dr. Jesamyn Fuscardo Marshall envisions transitioning to the role of Director of the emergency department and starting an urgent care facility in her father's name. Her long-term goal includes operating her own urgent care and establishing a chain of facilities in her area, further expanding access to quality healthcare. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive Change

100 Deals associated with Marshall University

100 Translational Medicine associated with Marshall University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 01 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Thiomethyl-bound derivatives (Marshall University)	Aspergillus Meningitis More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis